<< HTHH and Soles4Souls team up to provide athletic shoes for Tennessee children | Malaria experts urge Congress to increase funding for malaria programs >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Dansk | Nederlands | Bahasa | Русский | Svenska | Polski

Aperio Technologies receives U.S. patent for client/server image analysis

Published on November 19, 2009 at 3:35 AM · No Comments

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,602,524 entitled "Image Processing and Analysis Framework."

The ‘524 patent describes a system and method for processing and analyzing digital slide images comprised of an algorithm server that executes image analysis algorithms on digital (whole) slide images, or on sub-regions of a digital slide image.

With this patent, Aperio extends its intellectual property portfolio to image analysis processing using a client/server architecture and distribution of digital pathology information, including support for multiple servers. A client/server architecture is a key aspect of making digital pathology useful in large labs, facilitating a more efficient workflow for busy clinicians and researchers.

Image analysis is a cutting-edge capability that uses automated analytical techniques and computer algorithms to extract quantitative information from the digital slide image, facilitating pathological interpretation. The ability to efficiently apply image analysis algorithms to digital slides is essential to automating tedious or repetitive analysis tasks such as counting cells or classifying tissue.

Aperio has a suite of image analysis applications that can be tuned for different tissue types (e.g. breast, colon, prostate), stains (e.g. HER2, ER, PR, Ki-67, P53, EGFR), reagents (e.g. Dako, Ventana) or to correlate algorithm results with other test methods (e.g. FISH, CISH). Aperio currently has FDA-cleared applications for HER2, ER and PR stained breast specimens for clinical use in pathology.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading